About this Journal Submit a Manuscript Table of Contents
Mediators of Inflammation
Volume 2013 (2013), Article ID 750540, 14 pages
http://dx.doi.org/10.1155/2013/750540
Review Article

Update on the Protective Molecular Pathways Improving Pancreatic Beta-Cell Dysfunction

1Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genova, Italy
2Division of Cardiology, Geneva University Hospitals, Faculty of Medicine, Foundation for Medical Researches, Avenue de la Roseraie 64, 1211 Geneva 4, Switzerland
3First Medical Clinic, Laboratory of Phagocyte Physiopathology and Inflammation, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genova, Italy

Received 5 February 2013; Accepted 10 April 2013

Academic Editor: Oreste Gualillo

Copyright © 2013 Alessandra Puddu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Rorsman, “The pancreatic beta-cell as a fuel sensor: an electrophysiologist's viewpoint,” Diabetologia, vol. 40, no. 5, pp. 487–495, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. S. E. Kahn, “Clinical review 135: the importance of β-cell failure in the development and progression of type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 9, pp. 4047–4058, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Lin and Z. Sun, “Current views on type 2 diabetes,” Journal of Endocrinology, vol. 204, no. 1, pp. 1–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Stumvoll, B. J. Goldstein, and T. W. van Haeften, “Type 2 diabetes: principles of pathogenesis and therapy,” The Lancet, vol. 365, no. 9467, pp. 1333–1346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Rorsman, L. Eliasson, E. Renström, J. Gromada, S. Barg, and S. Göpel, “The cell physiology of biphasic insulin secretion,” News in Physiological Sciences, vol. 15, no. 2, pp. 72–77, 2000. View at Scopus
  6. D. Ross Laybutt, H. Kaneto, W. Hasenkamp et al., “Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to β-cell survival during chronic hyperglycemia,” Diabetes, vol. 51, no. 2, pp. 413–423, 2002. View at Scopus
  7. J. C. Jonas, A. Sharma, W. Hasenkamp et al., “Chronic hyperglycemia triggers loss of pancreatic β cell differentiation in an animal model of diabetes,” Journal of Biological Chemistry, vol. 274, no. 20, pp. 14112–14121, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Tokuyama, J. Sturis, A. M. DePaoli et al., “Evolution of β-cell dysfunction in the male Zucker diabetic fatty rat,” Diabetes, vol. 44, no. 12, pp. 1447–1457, 1995. View at Scopus
  9. V. Poitout, J. Amyot, M. Semache, B. Zarrouki, D. Hagman, and G. Fontés, “Glucolipotoxicity of the pancreatic beta cell,” Biochimica et Biophysica Acta, vol. 1801, no. 3, pp. 289–298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Poitout and R. P. Robertson, “Minireview: secondary β-cell failure in type 2 diabetes: a convergence of glucotoxicity and lipotoxicity,” Endocrinology, vol. 143, no. 2, pp. 339–342, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Cnop, J. Vidal, R. L. Hull et al., “Progressive loss of β-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes,” Diabetes Care, vol. 30, no. 3, pp. 677–682, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Robertson, H. Zhou, T. Zhang, and J. S. Harmon, “Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in type 2 diabetes,” Cell Biochemistry and Biophysics, vol. 48, no. 2-3, pp. 139–146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. R. P. Robertson, “β-Cell deterioration during diabetes: what's in the gun?” Trends in Endocrinology and Metabolism, vol. 20, no. 8, pp. 388–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. L. Eizirik, A. K. Cardozo, and M. Cnop, “The role for endoplasmic reticulum stress in diabetes mellitus,” Endocrine Reviews, vol. 29, no. 1, pp. 42–61, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Inaba, H. Mizukami, K. Kamata, K. Takahashi, K. Tsuboi, and S. Yagihashi, “Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats,” European Journal of Pharmacology, vol. 691, no. 1–3, pp. 297–306, 2012. View at Publisher · View at Google Scholar
  16. J. A. Pospisilik, J. Martin, T. Doty et al., “Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats,” Diabetes, vol. 52, no. 3, pp. 741–750, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. M. K. Reimer, J. J. Holst, and B. Ahrén, “Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice,” European Journal of Endocrinology, vol. 146, no. 5, pp. 717–727, 2002. View at Scopus
  18. Q. Wang and P. Brubaker, “Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice,” Diabetologia, vol. 45, no. 9, pp. 1263–1273, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Tourrel, D. Bailbe, M. Lacorne, M. J. Meile, M. Kergoat, and B. Portha, “Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4,” Diabetes, vol. 51, no. 5, pp. 1443–1452, 2002. View at Scopus
  20. R. Perfetti, J. I. E. Zhou, M. E. Doyle, and J. M. Egan, “Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats,” Endocrinology, vol. 141, no. 12, pp. 4600–4605, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Farilla, H. Hongxiang, C. Bertolotto et al., “Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats,” Endocrinology, vol. 143, no. 11, pp. 4397–4408, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Thorens, “Expression cloning of the pancreatic β cell receptor for the gluco- incretin hormone glucagon-like peptide 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 18, pp. 8641–8645, 1992. View at Scopus
  23. P. L. Brubaker and D. J. Drucker, “Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system,” Endocrinology, vol. 145, no. 6, pp. 2653–2659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Haq, K. Sheth, M. Abdullatif, F. A. A. Jabbar, C. Hamilton, and S. Al-Sedairy, “Suppression/stimulation of chemiluminescence by human seminal plasma,” Clinica Chimica Acta, vol. 200, no. 1, pp. 67–69, 1991. View at Publisher · View at Google Scholar · View at Scopus
  25. D. J. Drucker, “Glucagon-Like Peptide-1 and the Islet β-Cell: augmentation of Cell Proliferation and Inhibition of Apoptosis,” Endocrinology, vol. 144, no. 12, pp. 5145–5148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. X. Wang, J. Zhou, M. E. Doyle, and J. M. Egan, “Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism,” Endocrinology, vol. 142, no. 5, pp. 1820–1827, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. Hussain, D. L. Porras, M. H. Rowe et al., “Increased pancreatic β-cell proliferation mediated by CREB binding protein gene activation,” Molecular and Cellular Biology, vol. 26, no. 20, pp. 7747–7759, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. D. A. Stoffers, T. J. Kieffer, M. A. Hussain et al., “Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas,” Diabetes, vol. 49, no. 5, pp. 741–748, 2000. View at Scopus
  29. J. Buteau, W. El-Assaad, C. J. Rhodes, L. Mosenberg, E. Joly, and M. Prentki, “Glucagon-like peptide-1 prevents beta cell glucolipotoxicity,” Diabetologia, vol. 47, no. 5, pp. 806–815, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Puddu, D. Storace, A. Durante, P. Odetti, and G. L. Viviani, “Glucagon-like peptide-1 counteracts the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T 15,” Biochemical and Biophysical Research Communications, vol. 398, no. 3, pp. 462–466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. M. Lambeir, C. Durinx, S. Scharpé, and I. De Meester, “Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV,” Critical Reviews in Clinical Laboratory Sciences, vol. 40, no. 3, pp. 209–294, 2003. View at Scopus
  32. L. K. Phillips and J. B. Prins, “Update on incretin hormones,” Annals of the New York Academy of Sciences, vol. 1243, pp. E55–E74, 2011. View at Publisher · View at Google Scholar
  33. F. K. Knop, T. Vilsbøll, and J. J. Holst, “Incretin-based therapy of type 2 diabetes mellitus,” Current Protein and Peptide Science, vol. 10, no. 1, pp. 46–55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Vilsbøll and F. K. Knop, “Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus,” BioDrugs, vol. 22, no. 4, pp. 251–257, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. E. J. Verspohl, “Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors,” Pharmacology and Therapeutics, vol. 124, no. 1, pp. 113–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. A. Ross and J. M. Ekoé, “Incretin agents in type 2 diabetes,” Canadian Family Physician, vol. 56, no. 7, pp. 639–648, 2010. View at Scopus
  37. Y. M. Cho and T. J. Kieffer, “New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser,” Diabetologia, vol. 54, no. 2, pp. 219–222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. G. G. Graham, J. Punt, M. Arora et al., “Clinical pharmacokinetics of metformin,” Clinical Pharmacokinetics, vol. 50, no. 2, pp. 81–98, 2011. View at Publisher · View at Google Scholar
  39. M. L. Reitman and E. E. Schadt, “Pharmacogenetics of metformin response: a step in the path toward personalized medicine,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1226–1229, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. M. R. Owen, E. Doran, and A. P. Halestrap, “Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain,” Biochemical Journal, vol. 348, no. 3, pp. 607–614, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Y. El-Mir, V. Nogueira, E. Fontaine, N. Avéret, M. Rigoulet, and X. Leverve, “Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I,” Journal of Biological Chemistry, vol. 275, no. 1, pp. 223–228, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Maida, B. J. Lamont, X. Cao, and D. J. Drucker, “Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice,” Diabetologia, vol. 54, no. 2, pp. 339–349, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Patanè, S. Piro, A. M. Rabuazzo, M. Anello, R. Vigneri, and F. Purrello, “Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic β-cells,” Diabetes, vol. 49, no. 5, pp. 735–740, 2000. View at Scopus
  45. P. Marchetti, S. Del Guerra, L. Marselli et al., “Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp. 5535–5541, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. I. Leclerc, W. W. Woltersdorf, G. Da Silva Xavier et al., “Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion,” The American Journal of Physiology, vol. 286, no. 6, pp. E1023–E1031, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. B. A. Kefas, Y. Cai, K. Kerckhofs et al., “Metformin-induced stimulation of AMP-activated protein kinase in β-cells impairs their glucose responsiveness and can lead to apoptosis,” Biochemical Pharmacology, vol. 68, no. 3, pp. 409–416, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. C. F. Sum, J. M. Webster, A. B. Johnson, C. Catalano, B. G. Cooper, and R. Taylor, “The effect of intravenous metformin on glucose metabolism during hyperglycaemia in Type 2 diabetes,” Diabetic Medicine, vol. 9, no. 1, pp. 61–65, 1992. View at Scopus
  49. C. Wilcock and C. J. Bailey, “Accumulation of metformin by tissues of the normal and diabetic mouse,” Xenobiotica, vol. 24, no. 1, pp. 49–57, 1994. View at Scopus
  50. B. M. Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. D. S. Bell, “Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus,” Postgraduate Medicine, Spec No, pp. 35–44, 2003. View at Scopus
  52. I. W. Campbell and S. Mariz, “β-Cell preservation with thiazolidinediones,” Diabetes Research and Clinical Practice, vol. 76, no. 2, pp. 163–176, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Ao, Y. Huo, L. Qi, Z. Xiong, L. Xue, and Y. Qi, “Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kB,” Cell Biology International, vol. 34, no. 7, pp. 723–730, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. X. Liu, D. Luo, M. Zheng, Y. Hao, L. Hou, and S. Zhang, “Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NAPDH oxidase and NF kappa B activation,” European Journal of Pharmacology, vol. 629, no. 1–3, pp. 153–158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Saitoh, C. Chun-ping, K. Noma, H. Ueno, M. Mizuta, and M. Nakazato, “Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic β-cells,” Diabetes, Obesity and Metabolism, vol. 10, no. 7, pp. 564–573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. A. R. Diani, G. Sawada, B. Wyse, F. T. Murray, and M. Khan, “Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes,” The American Journal of Physiology, vol. 286, no. 1, pp. E116–E122, 2004. View at Scopus
  57. Y. Miyazaki and R. A. Defronzo, “Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients,” Diabetes, Obesity and Metabolism, vol. 10, no. 12, pp. 1204–1211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Zeender, K. Maedler, D. Bosco, T. Berney, M. Y. Donath, and P. A. Halban, “Pioglitazone and sodium salicylate protect human β-cells against apoptosis and impaired function induced by glucose and interleukin-1β,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 10, pp. 5059–5066, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Kawasaki, M. Matsuda, Y. Kanda, H. Inoue, and K. Kaku, “Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice,” The American Journal of Physiology, vol. 288, no. 3, pp. E510–E518, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Ishida, M. Takizawa, S. Ozawa et al., “Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: possible protection of β cells from oxidative stress,” Metabolism, vol. 53, no. 4, pp. 488–494, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Y. Lin, T. Gurlo, L. Haataja, W. A. Hsueh, and P. C. Butler, “Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 12, pp. 6678–6686, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Kono, G. Ahn, D. R. Moss et al., “PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress,” Molecular Endocrinology, vol. 26, no. 2, pp. 257–271, 2012. View at Publisher · View at Google Scholar
  63. A. Puddu, R. Sanguineti, A. Durante, and G. L. Viviani, “Pioglitazone attenuates the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T15,” Regulatory Peptides, vol. 177, no. 1-3, pp. 79–84, 2012. View at Publisher · View at Google Scholar
  64. A. D. Kohn, K. S. Kovacina, and R. A. Roth, “Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase,” EMBO Journal, vol. 14, no. 17, pp. 4288–4295, 1995. View at Scopus
  65. T. F. Franke, “Intracellular signaling by Akt: bound to be specific,” Science Signaling, vol. 1, no. 24, p. pe29, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Bernal-Mizrachi, W. Wen, S. Stahlhut, C. M. Welling, and M. A. Permutt, “Islet β cell expression of constitutively active Akt1/PKBα induces striking hypertrophy, hyperplasia, and hyperinsulinemia,” Journal of Clinical Investigation, vol. 108, no. 11, pp. 1631–1638, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. R. L. Tuttle, N. S. Gill, W. Pugh et al., “Regulation of pancreatic β-cell growth and survival by the serine/threonine protein kinase Akt1/PKBα,” Nature Medicine, vol. 7, no. 10, pp. 1133–1137, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Bernal-Mizrachi, S. Fatrai, J. D. Johnson et al., “Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet β cells,” Journal of Clinical Investigation, vol. 114, no. 7, pp. 928–936, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Kasuga, “Insulin resistance and pancreatic β cell failure,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1756–1760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Dor, J. Brown, O. I. Martinez, and D. A. Melton, “Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation,” Nature, vol. 429, no. 6987, pp. 41–46, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Georgia and A. Bhushan, “β cell replication is the primary mechanism for maintaining postnatal β cell mass,” Journal of Clinical Investigation, vol. 114, no. 7, pp. 963–968, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. J. A. Kushner, M. A. Ciemerych, E. Sicinska et al., “Cyclins D2 and D1 are essential for postnatal pancreatic β-cell growth,” Molecular and Cellular Biology, vol. 25, no. 9, pp. 3752–3762, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Fatrai, L. Elghazi, N. Balcazar et al., “Akt induces β-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity,” Diabetes, vol. 55, no. 2, pp. 318–325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. D. J. Burks and M. F. White, “IRS proteins and beta-cell function,” Diabetes, vol. 50, supplement 1, pp. S140–145, 2001. View at Scopus
  75. L. Elghazi and E. Bernal-Mizrachi, “Akt and PTEN: β-cell mass and pancreas plasticity,” Trends in Endocrinology and Metabolism, vol. 20, no. 5, pp. 243–251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. Z. Liu and J. F. Habener, “Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation,” Journal of Biological Chemistry, vol. 283, no. 13, pp. 8723–8735, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. Q. Wang, L. Li, E. Xu, V. Wong, C. Rhodes, and P. L. Brubaker, “Glucagon-like peptitle-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells,” Diabetologia, vol. 47, no. 3, pp. 478–487, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Buteau, S. Foisy, E. Joly, and M. Prentki, “Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor,” Diabetes, vol. 52, no. 1, pp. 124–132, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Buteau, M. L. Spatz, and D. Accili, “Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass,” Diabetes, vol. 55, no. 5, pp. 1190–1196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. U. S. Jhala, G. Canettieri, R. A. Screaton et al., “cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2,” Genes and Development, vol. 17, no. 13, pp. 1575–1580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Srinivasan, E. Bernal-Mizrachi, M. Ohsugi, and M. A. Permutt, “Glucose promotes pancreatic islet β-cell survival through a PI 3-kinase/Akt-signaling pathway,” The American Journal of Physiology, vol. 283, no. 4, pp. E784–E793, 2002. View at Scopus
  82. L. M. Dickson and C. J. Rhodes, “Pancreatic β-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt?” The American Journal of Physiology, vol. 287, no. 2, pp. E192–E198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. C. E. Wrede, L. M. Dickson, M. K. Lingohr, I. Briaud, and C. J. Rhodes, “Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic β-cells (INS-1),” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49676–49684, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. T. A. Buchanan, A. H. Xiang, R. K. Peters et al., “Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women,” Diabetes, vol. 51, no. 9, pp. 2796–2803, 2002. View at Scopus
  85. F. Ovalle and D. S. H. Bell, “Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with type 2 diabetes,” Diabetes Care, vol. 27, no. 11, pp. 2585–2589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. C. J. Rhodes, “Type 2 diabetes: a matter of β-cell life and death?” Science, vol. 307, no. 5708, pp. 380–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Ron and P. Walter, “Signal integration in the endoplasmic reticulum unfolded protein response,” Nature Reviews Molecular Cell Biology, vol. 8, no. 7, pp. 519–529, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. D. T. Rutkowski and R. J. Kaufman, “A trip to the ER: coping with stress,” Trends in Cell Biology, vol. 14, no. 1, pp. 20–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Ron, “Translational control in the endoplasmic reticulum stress response,” Journal of Clinical Investigation, vol. 110, no. 10, pp. 1383–1388, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. R. C. Wek, H. Y. Jiang, and T. G. Anthony, “Coping with stress: eIF2 kinases and translational control,” Biochemical Society Transactions, vol. 34, pp. 7–11, 2006.
  91. J. Wu and R. J. Kaufman, “From acute ER stress to physiological roles of the unfolded protein response,” Cell Death and Differentiation, vol. 13, no. 3, pp. 374–384, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. L. Zhang, E. Lai, T. Teodoro, and A. Volchuk, “GRP78, but not protein-disulfide isomerase, partially reverses hyperglycemia-induced inhibition of insulin synthesis and secretion in pancreatic β-cells,” Journal of Biological Chemistry, vol. 284, no. 8, pp. 5289–5298, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Wang, X. R. Zhao, P. Wang et al., “Glucose regulated proteins 78 protects insulinoma cells (NIT-1) from death induced by streptozotocin, cytokines or cytotoxic T lymphocytes,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 11, pp. 2076–2082, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Gotoh, K. Terada, S. Oyadomari, and M. Mori, “hsp70-DnaJ chaperone pair prevents nitric oxide- and CHOP-induced apoptosis by inhibiting translocation of Bax to mitochondria,” Cell Death and Differentiation, vol. 11, no. 4, pp. 390–402, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Cnop, L. Ladrière, M. Igoillo-Esteve, R. F. Moura, and D. A. Cunha, “Causes and cures for endoplasmic reticulum stress in lipotoxic β-cell dysfunction,” Diabetes, Obesity and Metabolism, vol. 12, supplement 2, pp. 76–82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. S. E. Choi, Y. J. Lee, H. J. Jang et al., “A chemical chaperone 4-PBA ameliorates palmitate-induced inhibition of glucose-stimulated insulin secretion (GSIS),” Archives of Biochemistry and Biophysics, vol. 475, no. 2, pp. 109–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. D. A. Cunha, L. Ladrière, F. Ortis et al., “Glucagon-like peptide-1 agonists protect pancreatic β-cells from lipotoxic endoplasmic reticulum stress through upregulation of BIP and JunB,” Diabetes, vol. 58, no. 12, pp. 2851–2862, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. B. Yusta, L. L. Baggio, J. L. Estall et al., “GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress,” Cell Metabolism, vol. 4, no. 5, pp. 391–406, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. G. Drews, P. Krippeit-Drews, and M. Dufer, “Electrophysiology of islet cells,” Advances in Experimental Medicine and Biology, vol. 654, pp. 115–163, 2010.
  100. J. Lang, “Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion,” European Journal of Biochemistry, vol. 259, no. 1-2, pp. 3–17, 1999. View at Publisher · View at Google Scholar · View at Scopus
  101. H. F. Lodish and N. Kong, “Perturbation of cellular calcium blocks exit of secretory proteins from the rough endoplasmic reticulum,” Journal of Biological Chemistry, vol. 265, no. 19, pp. 10893–10899, 1990. View at Scopus
  102. F. Pena, A. Jansens, G. Van Zadelhoff, and I. Braakman, “Calcium as a crucial cofactor for low density lipoprotein receptor folding in the endoplasmic reticulum,” Journal of Biological Chemistry, vol. 285, no. 12, pp. 8656–8664, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. A. Hovnanian, “SERCA pumps and human diseases,” Sub-Cellular Biochemistry, vol. 45, pp. 337–363, 2007. View at Scopus
  104. C. E. Moore, O. Omikorede, E. Gomez, G. B. Willars, and T. P. Herbert, “PERK activation at low glucose concentration is mediated by SERCA pump inhibition and confers preemptive cytoprotection to pancreatic β-cells,” Molecular Endocrinology, vol. 25, no. 2, pp. 315–326, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. A. K. Cardozo, F. Ortis, J. Storling et al., “Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic β-cells,” Diabetes, vol. 54, no. 2, pp. 452–461, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. C. Evans-Molina, R. D. Robbins, T. Kono et al., “Peroxisome proliferator-activated receptor γ activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure,” Molecular and Cellular Biology, vol. 29, no. 8, pp. 2053–2067, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. M. W. Roe, L. H. Philipson, C. J. Frangakis et al., “Defective glucose-dependent endoplasmic reticulum Ca2+ sequestration in diabetic mouse islets of Langerhans,” Journal of Biological Chemistry, vol. 269, no. 28, pp. 18279–18282, 1994. View at Scopus
  108. J. Y. Kim, D. M. Lim, H. S. Park et al., “Exendin-4 protects against sulfonylurea-induced β-cell apoptosis,” Journal of Pharmacological Sciences, vol. 118, no. 1, pp. 65–74, 2012. View at Publisher · View at Google Scholar
  109. F. M. Matschinsky, “Glucokinase as glucose sensor and metabolic signal generator in pancreatic β-cells and hepatocytes,” Diabetes, vol. 39, no. 6, pp. 647–652, 1990. View at Scopus
  110. B. Glaser, P. Kesavan, M. Heyman et al., “Familial hyperinsulinism caused by an activating glucokinase mutation,” The New England Journal of Medicine, vol. 338, no. 4, pp. 226–230, 1998. View at Publisher · View at Google Scholar · View at Scopus
  111. G. Velho, P. Froguel, K. Clement et al., “Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young,” The Lancet, vol. 340, no. 8817, pp. 444–448, 1992. View at Publisher · View at Google Scholar · View at Scopus
  112. Y. Terauchi, I. Takamoto, N. Kubota et al., “Glucokinase and IRS-2 are required for compensatory β cell hyperplasia in response to high-fat diet-induced insulin resistance,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 246–257, 2007. View at Publisher · View at Google Scholar
  113. Y. Kajimoto, T. Matsuoka, H. Kaneto et al., “Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells,” Diabetologia, vol. 42, no. 12, pp. 1417–1424, 1999. View at Publisher · View at Google Scholar · View at Scopus
  114. F. M. Matschinsky, “Assessing the potential of glucokinase activators in diabetes therapy,” Nature Reviews Drug Discovery, vol. 8, no. 5, pp. 399–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Y. Ding, A. Nkobena, C. A. Kraft, M. L. Markwardt, and M. A. Rizzo, “Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic β cells,” Journal of Biological Chemistry, vol. 286, no. 19, pp. 16768–16774, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. K. Murao, J. Li, H. Imachi et al., “Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic β-cell line,” Diabetes, Obesity and Metabolism, vol. 11, no. 10, pp. 939–946, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Tiedge, S. Lortz, J. Drinkgern, and S. Lenzen, “Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells,” Diabetes, vol. 46, no. 11, pp. 1733–1742, 1997. View at Scopus
  118. J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky, “Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes,” Endocrine Reviews, vol. 23, no. 5, pp. 599–622, 2002. View at Publisher · View at Google Scholar · View at Scopus
  119. M. A. Gonzalez-Moles, I. Ruiz-Avila, A. Rodriguez-Archilla et al., “Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 95, no. 6, pp. 688–692, 2003. View at Publisher · View at Google Scholar · View at Scopus
  120. R. P. Robertson, J. Harmon, P. O. Tran, Y. Tanaka, and H. Takahashi, “Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection,” Diabetes, vol. 52, no. 3, pp. 581–587, 2003. View at Publisher · View at Google Scholar · View at Scopus
  121. S. G. Rhee, K. S. Yang, S. W. Kang, H. A. Woo, and T. S. Chang, “Controlled elimination of intracellular H2O2: regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification,” Antioxidants and Redox Signaling, vol. 7, no. 5-6, pp. 619–626, 2005. View at Publisher · View at Google Scholar · View at Scopus
  122. J. Pi, W. Qu, J. M. Reece, Y. Kumagai, and M. P. Waalkes, “Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide,” Experimental Cell Research, vol. 290, no. 2, pp. 234–245, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. T. Nguyen, P. J. Sherratt, and C. B. Pickett, “Regulatory mechanisms controlling gene expression mediated by the antioxidant response element,” Annual Review of Pharmacology and Toxicology, vol. 43, pp. 233–260, 2003. View at Publisher · View at Google Scholar · View at Scopus
  124. X. Wang and C. X. Hai, “ROS acts as a double-edged sword in the pathogenesis of type 2 diabetes mellitus: is Nrf2 a potential target for the treatment?” Mini-Reviews in Medicinal Chemistry, vol. 11, no. 12, pp. 1082–1092, 2011. View at Publisher · View at Google Scholar
  125. F. Q. Schafer and G. R. Buettner, “Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple,” Free Radical Biology and Medicine, vol. 30, no. 11, pp. 1191–1212, 2001. View at Publisher · View at Google Scholar · View at Scopus
  126. S. Numazawa, H. Sakaguchi, R. Aoki, T. Taira, and T. Yoshida, “Regulation of the susceptibility to oxidative stress by cysteine availability in pancreatic β-cells,” The American Journal of Physiology, vol. 295, no. 2, pp. C468–C474, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. G. A. Martens, Y. Cai, S. Hinke, G. Stangé, M. Van De Casteele, and D. Pipeleers, “Glucose suppresses superoxide generation in metabolically responsive pancreatic β cells,” Journal of Biological Chemistry, vol. 280, no. 21, pp. 20389–20396, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. Y. Tanaka, P. O. T. Tran, J. Harmon, and R. P. Robertson, “A role for glutathione peroxidase in protecting pancreatic β cells against oxidative stress in a model of glucose toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 19, pp. 12363–12368, 2002. View at Publisher · View at Google Scholar · View at Scopus
  129. V. P. Bindokas, A. Kuznetsov, S. Sreenan, K. S. Polonsky, M. W. Roe, and L. H. Philipson, “Visualizing superoxide production in normal and diabetic rat islets of Langerhans,” Journal of Biological Chemistry, vol. 278, no. 11, pp. 9796–9801, 2003. View at Publisher · View at Google Scholar · View at Scopus
  130. J. Pi, Y. Bai, Q. Zhang et al., “Reactive oxygen species as a signal in glucose-stimulated insulin secretion,” Diabetes, vol. 56, no. 7, pp. 1783–1791, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. S. Lortz, E. Gurgul-Convey, O. Naujok, and S. Lenzen, “Overexpression of the antioxidant enzyme catalase does not interfere with the glucose responsiveness of insulin-secreting INS-1E cells and rat islets,” Diabetologia, vol. 56, pp. 774–782, 2013.
  132. C. Leloup, C. Tourrel-Cuzin, C. Magnan et al., “Mitochondrial reactive oxygen species are obligatory signals for glucose-induced insulin secretion,” Diabetes, vol. 58, no. 3, pp. 673–681, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. M. Lagos-Quintana, R. Rauhut, W. Lendeckel, and T. Tuschl, “Identification of novel genes coding for small expressed RNAs,” Science, vol. 294, no. 5543, pp. 853–858, 2001. View at Publisher · View at Google Scholar · View at Scopus
  134. N. C. Lau, L. P. Lim, E. G. Weinstein, and D. P. Bartel, “An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans,” Science, vol. 294, no. 5543, pp. 858–862, 2001. View at Publisher · View at Google Scholar · View at Scopus
  135. R. C. Lee and V. Ambros, “An extensive class of small RNAs in Caenorhabditis elegans,” Science, vol. 294, no. 5543, pp. 862–864, 2001. View at Publisher · View at Google Scholar · View at Scopus
  136. O. Dumortier and E. Van Obberghen, “MicroRNAs in pancreas development,” Diabetes, Obesity and Metabolism, vol. 14, supplement 3, pp. 22–28.
  137. M. V. Joglekar, V. M. Joglekar, and A. A. Hardikar, “Expression of islet-specific microRNAs during human pancreatic development,” Gene Expression Patterns, vol. 9, no. 2, pp. 109–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. W. P. Kloosterman, A. K. Lagendijk, R. F. Ketting, J. D. Moulton, and R. H. Plasterk, “Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development,” PLoS Biology, vol. 5, no. 8, p. e203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  139. T. Melkman-Zehavi, R. Oren, S. Kredo-Russo et al., “miRNAs control insulin content in pancreatic beta-cells via downregulation of transcriptional repressors,” EMBO Journal, vol. 30, pp. 835–845, 2011.
  140. V. Plaisance, A. Abderrahmani, V. Perret-Menoud, P. Jacquemin, F. Lemaigre, and R. Regazzi, “MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells,” Journal of Biological Chemistry, vol. 281, no. 37, pp. 26932–26942, 2006. View at Publisher · View at Google Scholar · View at Scopus
  141. D. Ramachandran, U. Roy, S. Garg, S. Ghosh, S. Pathak, and U. Kolthur-Seetharam, “Sirt1 and mir-9 expression is regulated during glucose-stimulated insulin secretion in pancreatic β-islets,” FEBS Journal, vol. 278, no. 7, pp. 1167–1174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. X. Zhao, R. Mohan, S. Ozcan, and X. Tang, “MicroRNA-30d induces insulin transcription factor MafA and insulin production by targeting mitogen-activated protein 4 kinase 4 (MAP4K4) in pancreatic beta-cells,” Journal of Biological Chemistry, vol. 287, pp. 31155–31164, 2012.
  143. V. Bravo-Egana, S. Rosero, D. Klein et al., “Inflammation-mediated regulation of MicroRNA expression in transplanted pancreatic islets,” Journal of Transplantation, vol. 2012, Article ID 723614, 15 pages, 2012. View at Publisher · View at Google Scholar
  144. D. M. Keller, E. A. Clark, and R. H. Goodman, “Regulation of microRNA-375 by cAMP in pancreatic beta-cells,” Molecular Endocrinology, vol. 26, pp. 989–999, 2012.
  145. E. Roggli, S. Gattesco, D. Caille et al., “Changes in microRNA expression contribute to pancreatic beta-cell dysfunction in prediabetic NOD mice,” Diabetes, vol. 61, pp. 1742–1751, 2012.
  146. N. Wijesekara, L. H. Zhang, M. H. Kang et al., “miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets,” Diabetes, vol. 61, pp. 653–658, 2012.
  147. S. S. Andrali, M. L. Smapley, N. L. Vanderford, and S. Özcan, “Glucose regulation of insulin gene expression in pancreatic β-cells,” Biochemical Journal, vol. 415, no. 1, pp. 1–10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. K. Ohneda, H. Ee, and M. German, “Regulation of insulin gene transcription,” Seminars in Cell and Developmental Biology, vol. 11, no. 4, pp. 227–233, 2000. View at Publisher · View at Google Scholar · View at Scopus
  149. S. Shao, Z. Fang, X. Yu, and M. Zhang, “Transcription factors involved in glucose-stimulated insulin secretion of pancreatic beta cells,” Biochemical and Biophysical Research Communications, vol. 384, no. 4, pp. 401–404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. S. E. Samaras, L. Zhao, A. Means, E. Henderson, T. A. Matsuoka, and R. Stein, “The islet β cell-enriched RIPE3b1/Maf transcription factor regulates pdx-1 expression,” Journal of Biological Chemistry, vol. 278, no. 14, pp. 12263–12270, 2003. View at Publisher · View at Google Scholar · View at Scopus
  151. H. Wang, T. Brun, K. Kataoka, A. J. Sharma, and C. B. Wollheim, “MAFA controls genes implicated in insulin biosynthesis and secretion,” Diabetologia, vol. 50, no. 2, pp. 348–358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  152. H. Kaneto, T. Miyatsuka, D. Kawamori et al., “PDX-1 and MafA play a crucial role in pancreatic β-cell differentiation and maintenance of mature β-cell function,” Endocrine Journal, vol. 55, no. 2, pp. 235–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  153. C. Zhang, T. Moriguchi, M. Kajihara et al., “MafA is a key regulator of glucose-stimulated insulin secretion,” Molecular and Cellular Biology, vol. 25, no. 12, pp. 4969–4976, 2005. View at Publisher · View at Google Scholar · View at Scopus
  154. D. K. Hagman, L. B. Hays, S. D. Parazzoli, and V. Poitout, “Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans,” Journal of Biological Chemistry, vol. 280, no. 37, pp. 32413–32418, 2005. View at Publisher · View at Google Scholar · View at Scopus
  155. V. Poitout, D. Hagman, R. Stein, I. Artner, R. P. Robertson, and J. S. Harmon, “Regulation of the insulin gene by glucose and fatty acids,” Journal of Nutrition, vol. 136, no. 4, pp. 873–876, 2006. View at Scopus
  156. L. J. Elrick and K. Docherty, “Phosphorylation-dependent nucleocytoplasmic shuttling of pancreatic duodenal homeobox-1,” Diabetes, vol. 50, no. 10, pp. 2244–2252, 2001. View at Scopus
  157. W. M. Macfarlane, C. M. McKinnon, Z. A. Felton-Edkins, H. Cragg, R. F. L. James, and K. Docherty, “Glucose stimulates translocation of the homeodomain transcription factor PDX1 from the cytoplasm to the nucleus in pancreatic β-cells,” Journal of Biological Chemistry, vol. 274, no. 2, pp. 1011–1016, 1999. View at Publisher · View at Google Scholar · View at Scopus
  158. T. Shu, Y. Zhu, H. Wang, Y. Lin, Z. Ma, and X. Han, “Ages decrease insulin synthesis in pancreatic β-cell by repressing pdx-1 protein expression at the post-translational level,” PLoS ONE, vol. 6, no. 4, Article ID e18782, 2011. View at Publisher · View at Google Scholar · View at Scopus
  159. M. Alikhani, C. M. MacLellan, M. Raptis, S. Vora, P. C. Trackman, and D. T. Graves, “Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor,” The American Journal of Physiology, vol. 292, no. 2, pp. C850–C856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  160. R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt, “Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation,” Glycobiology, vol. 15, no. 7, pp. 16R–28R, 2005. View at Publisher · View at Google Scholar · View at Scopus
  161. Y. Saisho, T. Maruyama, H. Hirose, and T. Saruta, “Relationship between proinsulin-to-insulin ratio and advanced glycation endproducts in Japanese type 2 diabetic subjects,” Diabetes Research and Clinical Practice, vol. 78, no. 2, pp. 182–188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  162. H. Vlassara and M. R. Palace, “Diabetes and advanced glycation endproducts,” Journal of Internal Medicine, vol. 251, no. 2, pp. 87–101, 2002. View at Publisher · View at Google Scholar · View at Scopus
  163. D. Kawamori, Y. Kajimoto, H. Kaneto et al., “Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH2-terminal kinase,” Diabetes, vol. 52, no. 12, pp. 2896–2904, 2003. View at Publisher · View at Google Scholar · View at Scopus
  164. A. P. Robertson, “Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes,” Journal of Biological Chemistry, vol. 279, no. 41, pp. 42351–42354, 2004. View at Publisher · View at Google Scholar · View at Scopus
  165. A. Puddu, D. Storace, P. Odetti, and G. L. Viviani, “Advanced glycation end-products affect transcription factors regulating insulin gene expression,” Biochemical and Biophysical Research Communications, vol. 395, no. 1, pp. 122–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. Y. Gao, J. I. Miyazaki, and G. W. Hart, “The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosamine and this modification is correlated with its DNA binding activity and insulin secretion in min6 β-cells,” Archives of Biochemistry and Biophysics, vol. 415, no. 2, pp. 155–163, 2003. View at Publisher · View at Google Scholar · View at Scopus
  167. E. Bonora, “Protection of pancreatic beta-cells: is it feasible?” Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 1, pp. 74–83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  168. J. Buteau, R. Roduit, S. Susini, and M. Prentki, “Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)- cells,” Diabetologia, vol. 42, no. 7, pp. 856–864, 1999. View at Publisher · View at Google Scholar · View at Scopus
  169. H. Okamoto, M. L. Hribal, H. V. Lin, W. R. Bennett, A. Ward, and D. Accili, “Role of the forkhead protein FoxO1 in β cell compensation to insulin resistance,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 775–782, 2006. View at Publisher · View at Google Scholar · View at Scopus
  170. D. A. Glauser and W. Schlegel, “The emerging role of FOXO transcription factors in pancreatic β cells,” Journal of Endocrinology, vol. 193, no. 2, pp. 195–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  171. J. Buteau, A. Shlien, S. Foisy, and D. Accili, “Metabolic diapause in pancreatic β-cells expressing a gain-of-function mutant of the forkhead protein Foxo1,” Journal of Biological Chemistry, vol. 282, no. 1, pp. 287–293, 2007. View at Publisher · View at Google Scholar · View at Scopus
  172. C. Talchai, S. Xuan, H. V. Lin, L. Sussel, and D. Accili, “Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure,” Cell, vol. 150, pp. 1223–1234, 2012.
  173. T. Kitamura and Y. Ido Kitamura, “Role of FoxO proteins in pancreatic β cells,” Endocrine Journal, vol. 54, no. 4, pp. 507–515, 2007. View at Publisher · View at Google Scholar · View at Scopus
  174. J. Nakae, W. H. Biggs III, T. Kitamura et al., “Regulation of insulin action and pancreatic β-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1,” Nature Genetics, vol. 32, no. 2, pp. 245–253, 2002. View at Publisher · View at Google Scholar · View at Scopus
  175. D. Kawamori, H. Kaneto, Y. Nakatani et al., “The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation,” Journal of Biological Chemistry, vol. 281, no. 2, pp. 1091–1098, 2006. View at Publisher · View at Google Scholar · View at Scopus
  176. P. S. Corbet and D. D. Chadee, “The diel pattern of entry to outdoor oviposition sites by female Aedes aegypti (L.) (Diptera: Culicidae) that then laid eggs there: a preliminary study,” Annals of Tropical Medicine and Parasitology, vol. 86, no. 5, pp. 523–528, 1992. View at Scopus
  177. D. Fang, Z. Huang, H. Guan et al., “The Akt/FoxO1/p27 pathway mediates the proliferative action of liraglutide in beta cells,” Molecular Medicine Reports, vol. 5, pp. 233–238, 2012.
  178. E. Lai, G. Bikopoulos, M. B. Wheeler, M. Rozakis-Adcock, and A. Volchuk, “Differential activation of ER stress and apoptosis in response to chronically elevated free fatty acids in pancreatic β-cells,” The American Journal of Physiology, vol. 294, no. 3, pp. E540–E550, 2008. View at Publisher · View at Google Scholar · View at Scopus
  179. C. F. Deacon, “Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors,” Diabetes, Obesity and Metabolism, vol. 9, supplement 1, pp. 23–31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  180. S. Puri and M. Hebrok, “Diabetic beta cells: to be or not to be?” Cell, vol. 150, pp. 1103–1104, 2012.
  181. J. Pi, Q. Zhang, J. Fu et al., “ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function,” Toxicology and Applied Pharmacology, vol. 244, no. 1, pp. 77–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  182. J. Maher and M. Yamamoto, “The rise of antioxidant signaling-The evolution and hormetic actions of Nrf2,” Toxicology and Applied Pharmacology, vol. 244, no. 1, pp. 4–15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  183. B. Yang, J. Fu, H. Zheng et al., “Deficiency in the nuclear factor E2-related factor 2 renders pancreatic beta-cells vulnerable to arsenic-induced cell damage,” Toxicology and Applied Pharmacology, vol. 264, pp. 315–323, 2012.
  184. S. Lee, E. G. Hur, I. G. Ryoo, K. A. Jung, J. Kwak, and M. K. Kwak, “Involvement of the Nrf2-proteasome pathway in the endoplasmic reticulum stress response in pancreatic beta-cells,” Toxicology and Applied Pharmacology, vol. 264, pp. 431–438, 2012.
  185. E. R. Gilbert and D. Liu, “Epigenetics: the missing link to understanding beta-cell dysfunction in the pathogenesis of type 2 diabetes,” Epigenetics, vol. 7, pp. 841–852, 2012.